{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-009927","form_type":"8-K","ticker":null,"cik":"0001293310","company_name":"HUMANIGEN, INC","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.496967+00:00","generated_at":"2026-06-13T02:53:50.345080+00:00","sec_items":["3.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Humanigen to be delisted from Nasdaq July 26; warns of going concern, potential bankruptcy","bullets":["Nasdaq will suspend trading July 26, 2023; shares will move to OTC Pink Market.","Three directors resigned July 18-19 (Hohneker, Buxton, Xie) causing non-compliance with Nasdaq independence rules.","Business combination negotiations with private biopharma ended; no alternative financing obtained.","Company states it will not be able to continue as going concern; exploring restructuring including bankruptcy in Q3 2023.","Any bankruptcy may result in complete or substantial loss of value for common stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-009927","json":"https://secwatch.observer/filing/0001214659-23-009927.json","markdown":"https://secwatch.observer/filing/0001214659-23-009927.md","text":"https://secwatch.observer/filing/0001214659-23-009927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293310/000121465923009927/0001214659-23-009927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293310/000121465923009927/j7242308k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:53:50.345080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37abbd57390edc22d859d0b6d00ec27462454c10","claim":"HUMANIGEN, INC received a nasdaq noncompliance notice notice regarding board independence (rules 5605(b)(1), 5605(c)(2)).","evidence_excerpt":"Continued Listing Rule or Standard; Transfer of Listing. As a result of the below-reported resignations of three members of the board of directors (the “Board”) of Humanigen, Inc. (the “Company”), the Company notified The Nasdaq Stock Market of the Company’s non-compliance with each of Nasdaq Rule 5605(b)(1), which requires a Nasdaq-listed company to have a board of directors comprised of a majority of independent directors; and Nasdaq Rule 5605(c)(2), which requires a Nasdaq-listed company to have an audit committee of the board of directors comprised of at least three independent directors","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293310/000121465923009927/0001214659-23-009927-index.htm","confidence":0.92,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"board independence"},{"label":"Rules","value":"5605(b)(1), 5605(c)(2)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"7bafc622c5","claim":"Kevin Xie resigned as Director at HUMANIGEN, INC.","evidence_excerpt":"On July 18, 2023, John Hohneker resigned from the Board, and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293310/000121465923009927/0001214659-23-009927-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9573b1215c","claim":"Cheryl Buxton resigned as Director at HUMANIGEN, INC.","evidence_excerpt":"On July 18, 2023, John Hohneker resigned from the Board, and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293310/000121465923009927/0001214659-23-009927-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d86ced77e4","claim":"John Hohneker resigned as Director at HUMANIGEN, INC.","evidence_excerpt":"On July 18, 2023, John Hohneker resigned from the Board, and on July 19, 2023 Cheryl Buxton and Kevin Xie both resigned from the Board, in each case with immediate effect.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293310/000121465923009927/0001214659-23-009927-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}